Plus Therapeutics Inc (NASDAQ: PSTV) kicked off on Friday, up 9.07% from the previous trading day, before settling in for the closing price of $0.49. Over the past 52 weeks, PSTV has traded in a range of $0.16-$2.31.
A company in the Healthcare sector has jumped its sales by 46.51% annually for the last half of the decade. While this was happening, its average annual earnings per share was recorded 87.69%. With a float of $136.95 million, this company’s outstanding shares have now reached $137.43 million.
Plus Therapeutics Inc (PSTV) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Plus Therapeutics Inc is 0.35%, while institutional ownership is 5.82%. The most recent insider transaction that took place on Nov 04 ’25, was worth 10,200. In this transaction Chief Financial Officer of this company bought 20,000 shares at a rate of $0.51, taking the stock ownership to the 68,138 shares. Before that another transaction happened on Aug 22 ’25, when Company’s Director bought 110,000 for $0.49, making the entire transaction worth $53,779. This insider now owns 139,327 shares in total.
Plus Therapeutics Inc (PSTV) Latest Financial update
In the latest quarterly report, which was put into the public domain on 12/31/2024, the organization reported -0.49 earnings per share (EPS), higher than consensus estimate (set at -0.5) by 0.01. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.04 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 87.69% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 62.04% during the next five years compared to 46.51% growth over the previous five years of trading.
Plus Therapeutics Inc (NASDAQ: PSTV) Trading Performance Indicators
Take a look at Plus Therapeutics Inc’s (PSTV) current performance indicators. Last quarter, stock had a quick ratio of 1.27. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 13.92.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.90, a number that is poised to hit -0.03 in the next quarter and is forecasted to reach -0.14 in one year’s time.
Technical Analysis of Plus Therapeutics Inc (PSTV)
Let’s dig in a bit further. During the last 5-days, its volume was 8.73 million. That was inferior than the volume of 19.24 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 37.31%.
During the past 100 days, Plus Therapeutics Inc’s (PSTV) raw stochastic average was set at 39.39%, which indicates a significant decrease from 59.91% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.0489 in the past 14 days, which was lower than the 0.0673 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.5794, while its 200-day Moving Average is $0.6238. However, in the short run, Plus Therapeutics Inc’s stock first resistance to watch stands at $0.5510. Second resistance stands at $0.5694. The third major resistance level sits at $0.6047. If the price goes on to break the first support level at $0.4973, it is likely to go to the next support level at $0.4620. The third support level lies at $0.4436 if the price breaches the second support level.
Plus Therapeutics Inc (NASDAQ: PSTV) Key Stats
The company with the Market Capitalisation of 73.21 million has total of 137,429K Shares Outstanding. Its annual sales at the moment are 5,820 K in contrast with the sum of -12,980 K annual income. Company’s last quarter sales were recorded 1,400 K and last quarter income was -4,420 K.
